{"id":"NCT04642950","sponsor":"Nobelpharma","briefTitle":"A Phase II/III Study of Sargramostim","officialTitle":"A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-12-17","primaryCompletion":"2021-10-25","completion":"2021-10-25","firstPosted":"2020-11-24","resultsPosted":"2024-07-19","lastUpdate":"2024-07-19"},"enrollment":70,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"Sargramostim","otherNames":["Leukine"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"NPC-26","type":"EXPERIMENTAL"},{"label":"NP-26 Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, placebo-controlled, double-blind, group comparison, multicenter study to evaluate the efficacy and safety of inhalation administration of sargramostim for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment in COVID-19 patients.","primaryOutcome":{"measure":"2-rank Improvement on a 7-point Ordinal Scale","timeFrame":"Period until Day 28 (including the case after discharge).","effectByArm":[{"arm":"NPC-26","deltaMin":9,"sd":null},{"arm":"NP-26 Placebo","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":["37729076"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":47},"commonTop":["Constipation","White blood cell count increased","Hyperglycemia","Insomnia","Hepatocellular injury"]}}